8-K Announcements
6Material company update
Mar 25, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 25, 2026·SEC
Tevogen Bio Holdings Inc.(TVGN)Earnings, Financials & Key Ratios
TVGN•NASDAQ
$7.48
$1.48B mkt cap·Price updated May 7, 2026
AboutTevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.Show more
- Revenue$0
- EBITDA-$53M-528.0%
- Net Income-$10M+83.3%
- EPS (Diluted)-0.09-23300.0%
- Interest Coverage-291.05-742.7%
TVGN Key Insights
Tevogen Bio Holdings Inc. (TVGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 11.3% through buybacks
✗Weaknesses
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TVGN Price & Volume
Tevogen Bio Holdings Inc. (TVGN) stock price & volume — 10-year historical chart
Loading chart...
TVGN Growth Metrics
Tevogen Bio Holdings Inc. (TVGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-612.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.61%
Return on Capital
10 Years-892.72%
5 Years-892.72%
3 Years-1306.05%
Last Year-
TVGN Recent Earnings
Tevogen Bio Holdings Inc. (TVGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (60%)
Q2 2026Latest
Mar 31, 2026EPS
$1.20
Est $1.50
+20.0%
Revenue
—
Q4 2025
Nov 14, 2025EPS
$0.03
Est $0.06
+50.7%
Revenue
—
Q3 2025
Aug 19, 2025EPS
$0.03
Est $0.05
+40.0%
Revenue
—
Q2 2025
May 14, 2025EPS
$3.21
Est $0.05
-6494.4%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $1.20vs $1.50+20.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.03vs $0.06+50.7% | — |
| Q3 2025 | Aug 19, 2025 | $0.03vs $0.05+40.0% | — |
| Q2 2025 | May 14, 2025 | $3.21vs $0.05-6494.4% | — |
Based on last 12 quarters of dataView full earnings history →
TVGN Peer Comparison
Tevogen Bio Holdings Inc. (TVGN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 TGTX | 6.87B | 43.03 | 15.53 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ADMA | 2.03B | 8.47 | 14.12 | 19.63% | 32.43% | 38.97% | 0.17 | |
 NVAX | 1.5B | 9.23 | 3.63 | 64.69% | -14.73% | |||
 DYAI | 26.96M | 0.75 | -3.73 | 20.58% | -279.56% | -281.83% | 2.05 | |
 VXRT | 177.97M | 0.74 | 10.57 | 7.27% | 6.88% | 33.83% | 0.10 |
Compare TVGN vs Peers
Tevogen Bio Holdings Inc. (TVGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TVGN Income Statement
Tevogen Bio Holdings Inc. (TVGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 378.36K | 403.58K | 526.96K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -378.36K▲ 0% | -403.58K▼ 6.7% | -526.96K▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | -6.67% | - |
| Operating Expenses | 4.62M | 953.08K | 8.46M | 53.16M | 30.37M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 1.66M | 953.08K | 4.06M | 22.13M | 18.52M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 2.96M | 0 | 4.4M | 31.03M | 11.84M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.62M▲ 0% | -953.08K▲ 79.4% | -8.84M▼ 827.8% | -53.56M▼ 505.7% | -30.89M▲ 0% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 79.36% | -827.83% | -505.73% | - |
| EBITDA | -4.61M | 4.41M | -8.46M | -53.16M | -30.37M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | 195.65% | -292.01% | -528.03% | 33.71% |
| D&A (Non-Cash Add-back) | 9.38K | 0 | 378.36K | 403.58K | 526.96K |
| EBIT | -15M | 4.41M | -59.27M | -13.54M | -30.9M |
| Net Interest Income | -598.5K | 0 | -256.03K | -184.04K | -140.74K |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 598.5K | 0 | 256.03K | 184.04K | 140.74K |
| Other Income/Expense | -10.98M | 5.36M | -51.63M | 39.84M | -148.88K |
| Pretax Income | -15.6M▲ 0% | 4.41M▲ 128.3% | -60.48M▼ 1471.9% | -13.73M▲ 77.3% | -31.04M▲ 0% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.6M▲ 0% | 4.41M▲ 128.3% | -60.48M▼ 1471.9% | -10.11M▲ 83.3% | -30.85M▲ 0% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 128.26% | -1471.89% | 83.28% | -612.87% |
| Net Income (Continuing) | -15.6M | 4.41M | -60.48M | -13.73M | -31.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.33▲ 0% | 0.04▲ 111.1% | -0.00▼ 101.1% | -0.09▼ 23300.0% | -0.16▲ 0% |
| EPS Growth % | - | 111.12% | -101.09% | - | 47.61% |
| EPS (Basic) | -0.33 | 0.04 | -0.00 | -0.09 | - |
| Diluted Shares Outstanding | 47.93M | 120M | 165.42M | 146.67M | 196.03M |
| Basic Shares Outstanding | 47.93M | 120M | 165.42M | 146.67M | 196.03M |
| Dividend Payout Ratio | - | - | - | - | - |
TVGN Balance Sheet
Tevogen Bio Holdings Inc. (TVGN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 7.17M | 5.84M | 1.72M | 2.36M | 2.12M |
| Cash & Short-Term Investments | 7.12M | 5.48M | 1.05M | 1.28M | 1.04M |
| Cash Only | 7.12M | 5.48M | 1.05M | 1.28M | 1.04M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 158.82K | 158.82K |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 53.96K | 0 | 0 | 919.09K | 925.82K |
| Total Non-Current Assets | 485.27K | 1.9M | 3.78M | 1.1M | 2.37M |
| Property, Plant & Equipment | 142.62K | 1.31M | 928.51K | 524.93K | 1.62M |
| Fixed Asset Turnover | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 351.92M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -351.57M | 594.88K | 2.85M | 575.84K | 2.47M |
| Total Assets | 7.66M▲ 0% | 7.74M▲ 1.1% | 5.51M▼ 28.9% | 3.46M▼ 37.1% | 4.49M▲ 0% |
| Asset Turnover | - | - | - | - | 0.00x |
| Asset Growth % | - | 1.05% | -28.86% | -37.12% | 17.71% |
| Total Current Liabilities | 667.94K | 1.96M | 85.48M | 9.04M | 6.74M |
| Accounts Payable | 378K | 865.91K | 3.42M | 5.2M | 3.31M |
| Days Payables Outstanding | - | - | 3.3K | 4.7K | 3.02K |
| Short-Term Debt | 0 | 0 | 80.71M | 1.65M | 1.65M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 45.27K | 237.6K | 120.15K | 403.23K | 240.3K |
| Current Ratio | 10.74x | 2.98x | 0.02x | 0.26x | 0.26x |
| Quick Ratio | 10.74x | 2.98x | 0.02x | 0.26x | 0.26x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 23.48M | 39.73M | 14.45M | 1.09M | 5.58M |
| Long-Term Debt | 23.48M | 39.3M | 14.22M | 1M | 4.4M |
| Capital Lease Obligations | 0 | 432.73K | 234.86K | 5.8K | 2.33M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 87.18K | 285.01K |
| Total Liabilities | 24.15M | 41.69M | 99.93M | 10.14M | 12.32M |
| Total Debt | 23.48M | 40.01M | 95.42M | 2.89M | 7.53M |
| Net Debt | 16.36M | 34.52M | 94.37M | 1.6M | 6.49M |
| Debt / Equity | - | - | - | - | -0.96x |
| Debt / EBITDA | - | 9.08x | - | - | -0.25x |
| Net Debt / EBITDA | - | 7.83x | - | - | -0.21x |
| Interest Coverage | -7.72x | - | -34.54x | -291.05x | -219.56x |
| Total Equity | -16.49M▲ 0% | -33.95M▼ 105.9% | -94.43M▼ 178.1% | -6.67M▲ 92.9% | -7.82M▲ 0% |
| Equity Growth % | - | -105.91% | -178.13% | 92.93% | 9.26% |
| Book Value per Share | -0.34 | -0.28 | -0.57 | -0.05 | -0.04 |
| Total Shareholders' Equity | -16.49M | -33.95M | -94.43M | -6.67M | -7.82M |
| Common Stock | 63.88K | 61.88K | 12K | 17.8K | 19.74K |
| Retained Earnings | -17.14M | -39.18M | -99.66M | -113.39M | -134.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
TVGN Cash Flow Statement
Tevogen Bio Holdings Inc. (TVGN) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -5.27M | -8.66M | -8.17M | -12M | -12M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -64.09% | 5.6% | -46.84% | -109.95% |
| Net Income | -15.6M | -22.04M | -60.48M | -13.73M | -30.85M |
| Depreciation & Amortization | 9.38K | 230.82K | 378.36K | 403.58K | 262.77K |
| Stock-Based Compensation | 582.41K | 4.58M | 0 | 40.76M | 10.53M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 10.98M | 8.67M | 51.63M | -39.43M | 10.3M |
| Working Capital Changes | -1.25M | -96.92K | 293.2K | -5.49K | -3.44M |
| Change in Receivables | 0 | 0 | -267K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.09M | 0 | 1.11M | 1.69M | -959.94K |
| Cash from Investing | -109.73K | -479.04K | -133K | 0 | 0 |
| Capital Expenditures | -109.73K | -479.04K | -133K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 12.5M | 7.5M | 3.87M | 12.23M | 11.9M |
| Debt Issued (Net) | 12.5M | 7.5M | 4M | 1M | 3.4M |
| Equity Issued (Net) | 0 | 0 | -1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -342.98M | 0 | 0 |
| Other Financing | 0 | 0 | 342.86M | 229.33K | 1.5M |
| Net Change in Cash | 7.12M▲ 0% | -1.63M▼ 123.0% | -4.43M▼ 171.1% | 230.6K▲ 105.2% | -1.29M▲ 0% |
| Free Cash Flow | -5.38M▲ 0% | -9.13M▼ 69.6% | -8.3M▲ 9.1% | -12M▼ 44.5% | -13.19M▲ 0% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -69.65% | 9.09% | -44.49% | -20.75% |
| FCF per Share | -0.11 | -0.08 | -0.05 | -0.08 | -0.08 |
| FCF Conversion (FCF/Net Income) | 0.34x | -1.96x | 0.14x | 1.19x | 0.43x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
TVGN Key Ratios
Tevogen Bio Holdings Inc. (TVGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | 389.21% |
| Return on Invested Capital (ROIC) | -322.18% | -2597.18% | - | 667.24% |
| Debt / Equity | - | - | - | -0.96x |
| Interest Coverage | - | -34.54x | -291.05x | -219.56x |
| FCF Conversion | -1.96x | 0.14x | 1.19x | 0.43x |
TVGN SEC Filings & Documents
Tevogen Bio Holdings Inc. (TVGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
TVGN Frequently Asked Questions
Tevogen Bio Holdings Inc. (TVGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tevogen Bio Holdings Inc. (TVGN) grew revenue by 0.0% over the past year. Growth has been modest.
Tevogen Bio Holdings Inc. (TVGN) reported a net loss of $30.8M for fiscal year 2024.
Dividend & Returns
Tevogen Bio Holdings Inc. (TVGN) had negative free cash flow of $13.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More TVGN
Tevogen Bio Holdings Inc. (TVGN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates